Teplizumab's Real-World impact on type 1 diabetes under scrutiny
NCT ID NCT07360080
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 1,000 people with Stage 2 Type 1 Diabetes who have received teplizumab in routine care. Researchers will track how long it takes for the disease to progress to Stage 3 and assess quality of life. The goal is to see if teplizumab delays the need for insulin therapy in everyday medical practice.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
teplizumab
What this could lead to
If successful, this study could confirm that teplizumab effectively delays the onset of full-blown Type 1 Diabetes in real-world settings, improving long-term disease management.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by factors like patient selection. Teplizumab may not work for everyone, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Investigational Site Number: 3760001
RECRUITINGRamat Gan, 5265601, Israel
-
Investigational Site Number: 8400003
RECRUITINGAtlanta, Georgia, 30318-2538, United States
-
Investigational Site Number: 8400005
RECRUITINGSandy City, Utah, 84093, United States
-
Investigative Site Number: 3760002
RECRUITINGRamat Gan, 52621, Israel
-
Investigative Site Number: 3760003
RECRUITINGPetah Tikva, 4920235, Israel
-
Investigative Site Number: 7840001
RECRUITINGAbu Dhabi, United Arab Emirates
-
Investigative Site Number: 8400002
RECRUITINGSyosset, New York, 11791, United States
-
Investigative Site Number: 8400004
RECRUITINGAtlanta, Georgia, 30329-3102, United States